Shares of CytoSorbents CTSO fell 2.15% in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 27.27% year over year to ($0.08), which were in line with the estimate of ($0.08).
Revenue of $9,795,000 rose by 57.17% from the same period last year, which beat the estimate of $9,660,000.
Looking Ahead
CytoSorbents hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Aug 04, 2020
Time: 04:45 PM
ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1338510&tp_key=e984a6c557
Price Action
52-week high: $11.74
Company's 52-week low was at $3.49
Price action over last quarter: down 9.95%
Company Overview
CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries.The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
